Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

BACKGROUND: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have widely been used in advanced cancer. However, these drugs may also lead to serious adverse events. The present meta-analysis aimed to determine the overall incidence and risk of deaths due to VEGFR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hong, Shaodong, Fang, Wenfeng, Liang, Wenhua, Yan, Yue, Zhou, Ting, Qin, Tao, Wu, Xuan, Ma, Yuxiang, Zhao, Yuanyuan, Yang, Yunpeng, Hu, Zhihuang, Xue, Cong, Hou, Xue, Chen, Yue, Huang, Yan, Zhao, Hongyun, Zhang, Li
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199796/
https://ncbi.nlm.nih.gov/pubmed/25336977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S68386
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars